Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT05246345
Recruiting Observational

Venetoclax Resistance Landscape in Chronic Lymphocytic Leukemia

NCT05246345 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Clermont-Ferrand
Phase
Observational
Started
2022-03-07
Last updated
2024-01-09

Condition(s) studied

Chronic Lymphocytic LeukemiaCLLProgressive Chronic Lymphocytic LeukemiaRefractory Chronic Lymphocytic LeukemiaRelapsed Chronic Lymphocytic Leukemia

Study summary

The purpose of this study is to collect medical informations and samples from refractory and/or relapsed chronic lymphocytic leukemia during or after venetoclax treatment, in order to evaluate the frequency of resistance mechanisms.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age greater than or equal to 18 years old; * chronic lymphocytic leukemia diagnosis according to iwCLL criteria; * refractory and/or relapsed disease during or after venetoclax treatment; * tumor samples available. * Relapse might be progressive chronic lymphocytic leukemia or transformation into Richter syndrome. * Patients must be able to express their opposition to be enrolled in this study, if need be. * Patients must be affiliated at the French Social Security system Exclusion Criteria: Patients of their legal guardians refusing to participate \-

Primary outcome measure(s)

  • Frequency measurement of BCL2 gene mutations — immediately after the chronic lymphocytic leukemia progression
    Frequency measurement of BCL2 gene mutations in a cohort of refractory and/or relapsed chronic lymphocytic leukemia during or after venetoclax therapy

Trial sites (14)

FacilityCityRegionStatus
CHU d'Amiens Amiens France Not Yet Recruiting
CHU de Besançon Besançon France Not Yet Recruiting
Hopital AVICENNE Bobigny France Not Yet Recruiting
CHU clermont-ferrand Clermont-Ferrand France Not Yet Recruiting
CHU de Clermont Ferrand Clermont-Ferrand France Not Yet Recruiting
CHU Grenoble Grenoble France Not Yet Recruiting
CHRU de Lille Lille France Not Yet Recruiting
Centre LEON BERARD Lyon France Not Yet Recruiting
CHU de Montpellier Montpellier France Not Yet Recruiting
CHU Nancy Nancy France Not Yet Recruiting
Hopital Pitié Salpetrière Paris France Not Yet Recruiting
Hopital Haut LEVEQUE Pessac France Not Yet Recruiting
CHU de Reims Reims France Recruiting
IUCT Oncopole Toulouse France Not Yet Recruiting

More University Hospital, Clermont-Ferrand trials in France

Vulnerability and Risk of Neuropathic Pain in Cancer Recruiting
Impact of Migration History and Social Conditions on the Immuno-virological Control of HIV in Migrants in France Starting soon
Helping Osteoarthritis Patients to Walk With NSAID Recruiting
Ketoanalogue Supplementation for Muscle Protection in CKD 4 and 5 Patients With Moderately Low Protein Diet (KETO-PROT-ACTION) Recruiting
CARPEUS : Effect of Carvedilol on the Portosystemic Gradient as Measured by Endoscopic Ultrasound Recruiting

Other trials for the same condition

Study of the Metabolism in the Lymphatic Niche of CLL Recruiting
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Active, not recruiting
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL Recruiting
A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL Active, not recruiting
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL) Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05246345 on ClinicalTrials.gov ↗ ← All trials in France